The potential of urinary tests in the management of Kala-Azar

Kala Azar in South Asia: Current Status and Challenges Ahead

Volumn , Issue , 2011, Pages 69-90

  Noiri, Eisei ^a,b   Hamasaki, Yoshifumi ^b   Negishi, Kousuke ^b   Sugaya, Takeshi ^c   Doi, Kent ^b   Fujita, Toshiro ^b   Osada, Yukihisa ^d   Matsumoto, Yoshitsugu ^a,e   Jamil, Kazi M ^e  

^a JAPAN INTERNATIONAL COOPERATION AGENCY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Strategic and Regulatory Affairs Consulting Department   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e ICDDRB Clinical Sciences Division   (Bangladesh)

Author keywords

Dipstick urine test; Fatty acid binding protein 1; Interleukin 18; Kala azar; Leishmaniasis; Urinary biomarker

Indexed keywords

EID: 84881312774     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-94-007-0277-6_8     Document Type: Chapter

References (40)

1. Sundar S, Singh RK, Maurya R, et al. Serological diagnosis of Indian visceral leishmaniasis: direct agglutination test versus rK39 strip test. Trans R Soc Trop Med Hyg. 2006;100:533-7.
2. Singh DP, Sundar S, Mohapatra TM. The rK39 strip test is non-predictor of clinical status for kala-azar. BMC Res Notes. 2009;2:187.
3. Vaidya VS, Ferguson MA, Bonventre JV. Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol. 2008;48:463-3.
4. Hoste EA, Clermont G, Kersten A, et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care. 2006;10:R73.
5. Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005;365:1231-8.
6. Portilla D, Dent C, Sugaya T, et al. Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int. 2008;73:465-2.
7. Ichino M, Kuroyanagi Y, Kusaka M, et al. Increased urinary neutrophil gelatinase associated lipocalin levels in a rat model of upper urinary tract infection. J Urol. 2009;181:2326-1.
8. Alpizar-Alpizar W, Laerum OD, Illemann M, et al. Neutrophil gelatinase-associated lipocalin (NGAL/Lcn2) is upregulated in gastric mucosa infected with Helicobacter pylori. Virchows Arch. 2009;455:225-3.
9. Noiri E, Doi K, Negishi K, et al. Urinary fatty acid-binding protein 1: an early predictive biomarker of kidney injury. Am J Physiol Renal Physiol. 2009;296:F669-9.
10. Negishi K, Noiri E, Doi K, et al. Monitoring of urinary L-type fatty acid-binding protein predicts histological severity of acute kidney injury. Am J Pathol. 2009;174:1154-9.
11. Nakamura T, Sugaya T, Node K, Ueda Y, Koide H. Urinary excretion of liver-type fatty acidbinding protein in contrast medium-induced nephropathy. Am J Kidney Dis. 2006;47:439-4.
12. Dieterle F, Marrer E, Suzuki E, Grenet O, Cordier A, Vonderscher J. Monitoring kidney safety in drug development: emerging technologies and their implications. Curr Opin Drug Discov Devel. 2008;11:60-1.
13. Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov. 2008;7:489-03.
14. Veerkamp JH, Paulussen RJ, Peeters RA, Maatman RG, van Moerkerk HT, van Kuppevelt TH. Detection, tissue distribution and (sub) cellular localization of fatty acid-binding protein types. Mol Cell Biochem. 1990;98:11-8.
15. Maatman RG, Van Kuppevelt TH, Veerkamp JH. Two types of fatty acid-binding protein in human kidney. Isolation, characterization and localization. Biochem J. 1991;273 Pt 3:759-6.
16. Doi K, Suzuki Y, Nakao A, Fujita T, Noiri E. Radical scavenger edaravone developed for clinical use ameliorates ischemia/reperfusion injury in rat kidney. Kidney Int. 2004;65:1714-3.
17. Yamamoto T, Tada T, Brodsky SV, et al. Intravital videomicroscopy of peritubular capillaries in renal ischemia. Am J Physiol Renal Physiol. 2002;282:F1150-5.
18. Noiri E, Nakao A, Uchida K, et al. Oxidative and nitrosative stress in acute renal ischemia. Am J Physiol Renal Physiol. 2001;281:F948-7.
19. Bonventre JV, Weinberg JM. Recent advances in the pathophysiology of ischemic acute renal failure. J Am Soc Nephrol. 2003;14:2199-210.
20. Thurman JM, Parikh CR. Peeking into the black box: new biomarkers for acute kidney injury. Kidney Int. 2008;73:379-1.
21. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303-10.
22. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348:1546-4.
23. Russell JA, Singer J, Bernard GR, et al. Changing pattern of organ dysfunction in early human sepsis is related to mortality. Crit Care Med. 2000;28:3405-1.
24. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. Jama. 2005;294:813-8.
25. Cruz DN, Perazella MA, Bellomo R, et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care. 2007;11:R47.
26. Nakamura T, Sugaya T, Koide H. Urinary liver-type fatty acid-binding protein in septic shock: effect of polymyxin B-immobilized fiber hemoperfusion. Shock. 2009;31:45-9.
27. Tanaka T, Noiri E, Yamamoto T, et al. Urinary human L-FABP is a potential biomarker to predict COX-inhibitor-induced renal injury. Nephron Exp Nephrol. 2008;108:e19-6.
28. Kamijo-Ikemori A, Sugaya T, Kimura K. Urinary fatty acid binding protein in renal disease. Clin Chim Acta. 2006;374:1-7.
29. Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H. Urinary liver-type fatty acidbinding protein levels for differential diagnosis of idiopathic focal glomerulosclerosis and minor glomerular abnormalities and effect of low-density lipoprotein apheresis. Clin Nephrol. 2006;65:1-6.
30. Nakamura T, Sugaya T, Kawagoe Y, et al. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci. 2007;333:321-6.
31. Nakamura T, Inoue T, Sugaya T, et al. Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy. Am J Hypertens. 2007;20:1195-01.
32. Hossain MI, Dodd NS, Ahmed T, et al. Experience in managing severe malnutrition in a government tertiary treatment facility in Bangladesh. J Health Popul Nutr. 2009;27:72-9.
33. Haase-Fielitz A, Haase M, Bellomo R. Instability of urinary NGAL during long-term storage. Am J Kidney Dis. 2009;53:564-5; author reply 6.
34. Zgheib NK, Capitano B, Branch RA, Chapter 14 Amphotericin B. In: DeBroe ME, Porter GA, Bennett WM, editors, Clinical nephrotoxins: renal injury from drugs and chemicals. Dordrecht: Springer; 2008. 323-51.
35. Yamamoto T, Noiri E, Ono Y, et al. Renal L-type fatty acid binding protein in acute ischemic injury. J Am Soc Nephrol. 2007;18:2894-02.
36. Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol. 1998;70:83-3.
37. Hailu A, van der Poll T, Berhe N, Kager PA. Elevated plasma levels of interferon (IFN) - gamma, IFN-gamma inducing cytokines, and IFN-gamma inducible CXC chemokines in visceral leishmaniasis. Am J Trop Med Hyg. 2004;71:561-7.
38. Parikh CR, Abraham E, Ancukiewicz M, Edelstein CL, Urine IL-. 18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. J Am Soc Nephrol. 2005;16:3046-2.
39. Maltezou HC. Drug resistance in visceral leishmaniasis. J Biomed Biotechnol. 2010; PMID: 19888437.
40. Yamamoto T, Noiri E, Ono Y, et al. Renal L-type fatty acid-binding protein in acute ischemic injury. J Am Soc Nephrol. 2007;18:2894-02.